The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism

Abstract The objective of this study was to determine the impact of calcium sensing receptor (CASR) A990G genetic polymorphism on parathyroid hormone (PTH) lowering response to cinacalcet treatment when controlling for significant influencing clinical factors. This retrospective study was conducted...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jaruwan Ngamkam, Somratai Vadcharavivad, Nutthada Areepium, Titinun Auamnoy, Kullaya Takkavatakarn, Pisut Katavetin, Khajohn Tiranathanagul, Kearkiat Praditpornsilpa, Somchai Eiam-Ong, Paweena Susantitaphong
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6ca6c890674641bb92bd0af8721a478a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6ca6c890674641bb92bd0af8721a478a
record_format	dspace
spelling	oai:doaj.org-article:6ca6c890674641bb92bd0af8721a478a2021-12-02T19:12:28ZThe impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism10.1038/s41598-021-97587-82045-2322https://doaj.org/article/6ca6c890674641bb92bd0af8721a478a2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97587-8https://doaj.org/toc/2045-2322Abstract The objective of this study was to determine the impact of calcium sensing receptor (CASR) A990G genetic polymorphism on parathyroid hormone (PTH) lowering response to cinacalcet treatment when controlling for significant influencing clinical factors. This retrospective study was conducted on 135 Thai hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). CASR A990G genotypes were determined. The patients were identified as either G carriers (heterozygous or homozygous CASR 990G allele carriers) or noncarriers (homozygous CASR 990A carriers). Tested covariates were baseline PTH level (bPTH), baseline serum phosphate (bPhos), baseline serum calcium (bCa), baseline calcitriol equivalent dose (bCtriol), baseline ergocalciferol dose (bErgo), and age. The ANCOVA showed that intact PTH levels after 12 weeks of cinacalcet treatment (PTHw12) was significantly lower among G carriers compared with noncarriers after controlling for bPTH, bPhos, bCtriol, and bErgo (F(1, 127) = 15.472, p < 0.001), with the adjusted mean difference of 253.7 pg/mL. The logistic regression analysis revealed that the odds of a G carrier achieving 30% PTH reduction after 12-week cinacalcet treatment were 3.968 times greater than the odds for a noncarrier after adjusting for bPhos, bCtriol, and age. In conclusion, the CASR A990G polymorphism significantly influences cinacalcet response in HD patients with SHPT.Jaruwan NgamkamSomratai VadcharavivadNutthada AreepiumTitinun AuamnoyKullaya TakkavatakarnPisut KatavetinKhajohn TiranathanagulKearkiat PraditpornsilpaSomchai Eiam-OngPaweena SusantitaphongNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jaruwan Ngamkam Somratai Vadcharavivad Nutthada Areepium Titinun Auamnoy Kullaya Takkavatakarn Pisut Katavetin Khajohn Tiranathanagul Kearkiat Praditpornsilpa Somchai Eiam-Ong Paweena Susantitaphong The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism
description	Abstract The objective of this study was to determine the impact of calcium sensing receptor (CASR) A990G genetic polymorphism on parathyroid hormone (PTH) lowering response to cinacalcet treatment when controlling for significant influencing clinical factors. This retrospective study was conducted on 135 Thai hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). CASR A990G genotypes were determined. The patients were identified as either G carriers (heterozygous or homozygous CASR 990G allele carriers) or noncarriers (homozygous CASR 990A carriers). Tested covariates were baseline PTH level (bPTH), baseline serum phosphate (bPhos), baseline serum calcium (bCa), baseline calcitriol equivalent dose (bCtriol), baseline ergocalciferol dose (bErgo), and age. The ANCOVA showed that intact PTH levels after 12 weeks of cinacalcet treatment (PTHw12) was significantly lower among G carriers compared with noncarriers after controlling for bPTH, bPhos, bCtriol, and bErgo (F(1, 127) = 15.472, p < 0.001), with the adjusted mean difference of 253.7 pg/mL. The logistic regression analysis revealed that the odds of a G carrier achieving 30% PTH reduction after 12-week cinacalcet treatment were 3.968 times greater than the odds for a noncarrier after adjusting for bPhos, bCtriol, and age. In conclusion, the CASR A990G polymorphism significantly influences cinacalcet response in HD patients with SHPT.
format	article
author	Jaruwan Ngamkam Somratai Vadcharavivad Nutthada Areepium Titinun Auamnoy Kullaya Takkavatakarn Pisut Katavetin Khajohn Tiranathanagul Kearkiat Praditpornsilpa Somchai Eiam-Ong Paweena Susantitaphong
author_facet	Jaruwan Ngamkam Somratai Vadcharavivad Nutthada Areepium Titinun Auamnoy Kullaya Takkavatakarn Pisut Katavetin Khajohn Tiranathanagul Kearkiat Praditpornsilpa Somchai Eiam-Ong Paweena Susantitaphong
author_sort	Jaruwan Ngamkam
title	The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism
title_short	The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism
title_full	The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism
title_fullStr	The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism
title_full_unstemmed	The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism
title_sort	impact of casr a990g polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6ca6c890674641bb92bd0af8721a478a
work_keys_str_mv	AT jaruwanngamkam theimpactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT somrataivadcharavivad theimpactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT nutthadaareepium theimpactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT titinunauamnoy theimpactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT kullayatakkavatakarn theimpactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT pisutkatavetin theimpactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT khajohntiranathanagul theimpactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT kearkiatpraditpornsilpa theimpactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT somchaieiamong theimpactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT paweenasusantitaphong theimpactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT jaruwanngamkam impactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT somrataivadcharavivad impactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT nutthadaareepium impactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT titinunauamnoy impactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT kullayatakkavatakarn impactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT pisutkatavetin impactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT khajohntiranathanagul impactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT kearkiatpraditpornsilpa impactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT somchaieiamong impactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism AT paweenasusantitaphong impactofcasra990gpolymorphisminresponsetocinacalcettreatmentinhemodialysispatientswithsecondaryhyperparathyroidism
_version_	1718377051102117888

The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism

Ejemplares similares